Press release article from our research archive:

GLAXO INC. RECEIVES CLEARANCE TO MARKET IMITREX(R) TABLETS IN U.S.

RESEARCH TRIANGLE PARK, N.C., June 2 /PRNewswire/ -- Glaxo Wellcome Inc. has received clearance from the United States Food and Drug Administration to market the tablet form of Imitrex(R) (sumatriptan succinate). Imitrex is the company's breakthrough therapy for the acute treatment of migraine and is currently available in the United States in subcutaneous (beneath the skin) injection form only.

The introduction of Imitrex Tablets will mark the availability of the first and only highly selective 5-HT(1) receptor-agonist migraine therapy in a tablet form. In worldwide markets, tablets account for more than 80 percent of sumatriptan sales.

Imitrex Tablets will be available ...

Related newspaper, magazine, and journal articles:

See all results. Or, try our Advanced Search.

Newsweek Harper's Magazine The Washington Post Chicago Tribune Crain's Chicago Business PRNewswire Pediatric News The Nation Advertising Age The Economist (US) A FREE trial gives you access to over 60 million articles! Access over 3,500 publications with a FREE trial!